FIELD: medicine; biotechnologies.
SUBSTANCE: DNA-vaccine is intended for activation of the immune response against the cancer cells, containing the design of DNA operably coding survivin protein and cytokine CCL21, built in attenuated vector Salmonella typhimurium. The way of inhibition of growth of a tumour by vaccine introduction under the invention to a mammal is opened. The product containing the described vaccine is presented. The way of vaccination of a mammal against a cancer where the way includes a stage of introduction to a mammal of effective quantity of the described DNA-vaccine causing the immune response is offered.
EFFECT: expansion of assortment of DNA-vaccines causing the immune response and unexpectedly high level of cytotoxicity against tumoral cells.
21 cl, 42 dwg, 6 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DNA COMPOSITION FOR INDUCING IMMUNE RESPONSE ON TUMOUR-ASSOCIATED MACROPHAGUES | 2007 |
|
RU2459631C2 |
| DNA VACCINE AGAINST PROLIFERATING ENDOTHELIAL CELLS AND USES THEREOF | 2003 |
|
RU2318019C2 |
| SURVIVIN-TARGETED ANTI-CANCER VACCINES AND APPLICATIONS THEREOF | 2018 |
|
RU2776949C2 |
| ANTI-CANCER VACCINES TARGETED WITH SURVIVIN AND THEIR APPLICATION | 2018 |
|
RU2751253C1 |
| FUSED PROTEIN OF TELOMERASE REVERSE TRANSCRIPTASE, NUCLEOTIDES CODING THEM, AND USING THEM | 2007 |
|
RU2473691C2 |
| COMPOSITION FOR TREATING LUNG CANCER, FIRST NON-SMALL CELLS LUNG CANCER (NSCLC) | 2008 |
|
RU2526510C2 |
| FUSED PROTEINS OF CARCINOEMBRYONAL ANTIGEN | 2005 |
|
RU2380375C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPY SCHEMES BASED ON VACCINES | 2013 |
|
RU2609651C2 |
| SURVIVIN PEPTIDE VACCINE | 2006 |
|
RU2396088C2 |
